Pfizer (PFE) Gets FDA Nod for Bivalent COVID Shot in Young Children

Pfizer PFE and partner BioNTech BNTX announced that the FDA broadened the label of their authorized Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for use as a single booster dose in children aged six months through four years.